Lone Pine Capital 13F: Cuts BSX Stake by $4.1M

Lone Pine Capital Reduces Position in Boston Scientific Corporation

Lone Pine Capital trimmed its investment in Boston Scientific Corporation NYSE:BSX during the reporting period, cutting its stake by 48.1%. The recent Form 13F filing with the SEC shows the fund parted ways with 97,048 shares. That left the firm holding 104,655 shares of the medical device maker, valued at roughly $4.46 million at the close of the period.

Cutting Back Shares in the Healthcare Firm

The reduction brought a notable shift to Lone Pine Capital's portfolio after previously holding 201,703 shares. Because Form 13F filings look backward at portfolio choices made at the end of the quarter, this filing reflects holdings as of May 15, 2026, and may not represent the investor's current position today. The transaction left the fund with a much smaller footprint in the Marlborough-based healthcare company.

Stock Valuation and Price Movement

Boston Scientific shares trade around $42.60, sitting near the lower end of their 52-week range that spans from a low of $41.39 to a high of $105.65. The stock changes hands well beneath its 50-day moving average of $46.18 and its 200-day moving average of $59.36. The company operates with a price-to-earnings ratio of 17.9 and a forward P/E ratio of 13.1, backed by a market capitalization of roughly $63.97 billion.

Analysts Set New Price Targets

Wall Street firms have kept a busy schedule of updates on the medical device maker through recent months. On October 14, 2026, Truist Securities maintained a Buy rating on the stock while adjusting its price target to $51 from $57. Earlier in the month, Barclays initiated coverage with an Equal-Weight rating and a $48 target on October 7, 2026. Citigroup maintained a Neutral rating with a $48 target on October 5, 2026, following a downgrade from the same firm on September 17, 2026, to a Neutral rating and a $50 target. Wells Fargo also maintained an Equal-Weight rating with a $48 target on September 24, 2026, while Oppenheimer kept an Outperform rating and lowered its target from $85 to $65 on September 21, 2026. BTIG maintained a Buy rating with a $56 target on September 9, 2026, and TD Cowen reiterated a Buy rating with a $56 target on August 25, 2026. The broader analyst community leans positive with a consensus Buy recommendation and a mean price target of $59.24 across 29 opinions.

Medical Technology Developer

Boston Scientific Corporation builds specialized medical equipment and devices used by doctors in interventional cardiology, rhythm management, and peripheral interventions. The company designs tools for gastrointestinal procedures, urology, and neuromodulation treatments such as deep brain stimulation. Founded in 1979 and headquartered in Massachusetts, it employs around 59,000 people globally to supply hospitals and surgical centers with diagnostic scopes, pacemakers, and cardiovascular support systems.

What to Watch at Boston Scientific Corporation

Investors tracking the stock can look toward the upcoming earnings report scheduled for October 28, 2026, for fresh financial results. Future regulatory filings will reveal whether other major institutional funds followed Lone Pine Capital's lead in trimming their positions. As always, historical 13F data captures past portfolio adjustments rather than live trading activity.